Document Detail

Bromocriptine therapy in acromegaly.
MedLine Citation:
PMID:  53655     Owner:  NLM     Status:  MEDLINE    
Bromocriptine (CB-154, Sandoz) has been given to 21 acromegalic patients (11 female, 10 male) for a period of 6-10 months. The mean serum growth-hormone (G.H.) levels ranged from 10 mug/1 to 512 mug/1 before therapy. Bromocriptine suppressed G.H. values to 5 mug/1 or less in 4 patients and to less than 10 mug/1 in a further 8 patients, but in 2 patients G.H. levels did not show any significant reduction. Bromocriptine did not block stress-induced G.H. secretion. It did not distrub pituitary function other than secretion of prolactin and had negligible side-effects. Its effect on tumour size is uncertain and it is therefore unsuitable for patients with suprasellar extension of the tumour. Otherwise it seems reasonable to offer a trial of bromocriptine to all patients with acromegaly where therapy is deemed necessary. In those who show a full response of G.H. levels with a dose of 20-40 mg of bromocriptine per day, external radiation to the pituitary can be used to prevent tumour expansion and bromocriptine withdrawn at intervals to assess the effect of the radiation. In patients with a partial response to bromocriptine, the decision to offer alternative therapy depends on the extent of the response and on the age and medical condition of the patient. In patients who fail to respond to bromocriptine, particularly those younger patients with active disease, more definitive local treatment (e.g., trans-sphenoidal removal of the tumour or yttrium-90 implantation) would be indicated. Bromocriptine may also be used with benefit in the large number of patients who have shown a partial response to other forms of therapy.
Y Sachdev; A Gomez-Pan; W M Tunbridge; A Duns; D R Weightman; R Hall; S K Goolamali
Related Documents :
6247105 - Functional significance of idiopathic adrenal calcification in the adult.
7920755 - Risk factors for secondary amenorrhea and galactorrhea.
9666875 - The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: co...
5212305 - Epidemiologic studies of carcinoma of the kidney. ii. association of renal adenoma with...
17308375 - Phospholipid transfer protein in hemodialysis patients.
22267475 - Liver follicular helper t-cells predict the achievement of virological response followi...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Lancet     Volume:  2     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1975 Dec 
Date Detail:
Created Date:  1976-02-20     Completed Date:  1976-02-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1164-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
11-Hydroxycorticosteroids / blood
Acromegaly / blood*,  drug therapy*
Administration, Oral
Blood Glucose / analysis
Bromocriptine / administration & dosage,  therapeutic use*
Clinical Trials as Topic
Drug Evaluation
Ergolines / therapeutic use*
Follicle Stimulating Hormone / blood
Growth Hormone / blood
Luteinizing Hormone / blood
Middle Aged
Pituitary Function Tests
Thyrotropin / blood
Thyrotropin-Releasing Hormone / diagnostic use
Time Factors
Reg. No./Substance:
0/11-Hydroxycorticosteroids; 0/Blood Glucose; 0/Ergolines; 24305-27-9/Thyrotropin-Releasing Hormone; 25614-03-3/Bromocriptine; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone; 9002-71-5/Thyrotropin; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Presenting features and diagnosis of rabies.
Next Document:  Treatment of osteoporosis of ageing with 1alpha-hydroxycholecalciferol.